Researchers have used self-propelling, radioactive nanoparticles to shrink bladder tumours by 90% in mice — and the secret ingredient is urine.
Bladder cancer doesn’t get much cultural airtime. It lacks the narrative weight of some other cancers, despite being one of the highest-incidence cancers in the world and the fourth most common tumour in men. Part of what makes it so persistently difficult to treat isn’t mortality — survival rates are relatively reasonable — it’s recurrence. Nearly half of bladder tumours resurface within five years, requiring ongoing monitoring, repeat treatments, and frequent hospital visits that collectively make it one of the most expensive cancers to manage. Patients can end up attending six to fourteen clinical appointments per treatment course. That’s a significant burden for what’s often framed as a “less serious” cancer. Phys.orgPhys.org
A team of researchers from the Institute for Bioengineering of Catalonia (IBEC), CIC biomaGUNE, and IRB Barcelona published results in Nature Nanotechnology in January 2024 that offer a genuinely different approach. They used self-propelling nanorobots — tiny, porous silica spheres — to deliver a radioactive payload directly to bladder tumours in mice. A single dose led to roughly a 90% reduction in tumour volume. PubMed Central
That’s worth sitting with for a moment. Not a modest improvement. Ninety percent.
So how does it actually work?
The nanobots are loaded with iodine-131, a radioisotope commonly used in targeted cancer therapy. The idea is straightforward in principle: get radioactive material into the tumour, let it do its damage locally, minimise collateral harm to surrounding tissue. The hard part is delivery — how do you get a nanoparticle to actually reach and penetrate a tumour rather than drift passively around the bladder?
The answer here is propulsion, and the fuel is urine. The nanobots are powered by urease, an enzyme that reacts with urea naturally present in urine to generate movement. This gives them a meaningful advantage over passive particles: they actively diffuse through the bladder environment rather than settling wherever gravity takes them. With current treatments, patients must physically reposition themselves every thirty minutes after drug administration to ensure coverage. These nanobots navigate that problem on their own. Nature
They also appear to penetrate tumour tissue in a way passive particles don’t. The researchers observed that the nanorobots break down the extracellular matrix of the tumour by locally increasing pH through their self-propelling chemical reaction, favouring penetration and accumulation within the tumour rather than the healthy urothelium. Tumour tissue, being spongier than healthy tissue, essentially let them in. PET imaging confirmed an eightfold increase in nanobot accumulation at the tumour site compared to surrounding tissue. News-MedicalPubMed Central
What this isn’t
This is a mouse study. Translating results from animal models to human patients is not a given, and the researchers themselves are careful about that framing. There are toxicity, dosing, and manufacturing questions that remain open. The next step the team has already flagged is determining whether tumours recur after treatment — which, for bladder cancer specifically, is the real test.
That said, the appeal of the concept goes beyond the headline number. The efficacy observed even at low doses suggests that the active motion of the nanobots — rather than sheer radioactive payload — is doing meaningful work, which opens the door to using this approach at doses low enough to reduce systemic side effects. That’s not a small thing. PubMed Central
The technology is now the basis of a spin-off company, Nanobots Therapeutics, founded in January 2023. Clinical application is still some distance away. But as proofs of concept go, this one is unusually clean.
Sources
- Simó, C. et al. (2024). Urease-powered nanobots for radionuclide bladder cancer therapy. Nature Nanotechnology, 19(4), 554–564. https://doi.org/10.1038/s41565-023-01577-y
- IBEC / Inside Precision Medicine coverage (January 2024): https://www.insideprecisionmedicine.com/topics/oncology/bladder-tumor-size-reduced-by-90-in-mouse-model-by-self-propelling-nanobots/
- Phys.org write-up (January 2024): https://phys.org/news/2024-01-dose-urea-powered-nanorobots-bladder.html
- News-Medical coverage with researcher quotes: https://www.news-medical.net/news/20240116/Urea-powered-nanorobots-reduce-bladder-tumors-by-9025-in-mice.aspx
- PMC full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC11026160/
